HOME >> BIOLOGY >> NEWS
JCI table of contents -- March 8, 2006

EDITORS PICK: Therapeutic peptide frees the protein p73 to kill tumor cells

The protein p53 suppresses tumor development by potently inducing tumor cell death, making it an obvious target for anticancer therapeutics. However, this therapeutic approach is confounded by the fact that genetic mutations cause loss or inactivation of p53 in approximately 50% of human cancers. As the p53-related protein p73, which can also induce tumor cell death, is rarely mutated in human cancers, researchers from the Beatson Institute for Cancer Research, United Kingdom, hypothesized that it might represent a more viable target than p53 for the development of broadly applicable anticancer therapeutics.

In the study, which appears online on March 8 in advance of publication in the April print issue of the Journal of Clinical Investigation, Kevin Ryan and colleagues show that a peptide of 37 amino acids in length, which they generated from human p53 (termed 37AA), killed both p53-sufficient and p53-deficient human tumor cell lines. 37AA mediated tumor cell death by binding to the negative regulator of p53-family proteins iASPP and preventing it from repressing the death-inducing function of p73. Furthermore, systemic administration of 37AA to mice with established tumors of human origin (both p53-sufficient and p53-deficient tumors) induced tumor regression in a p73-dependent manner. These data suggest that targeting the p73-mediated pathway of tumor cell death might provide a new avenue of research for the development of anticancer therapeutics.

TITLE: A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo

AUTHOR CONTACT:
Kevin M. Ryan
Beatson Institute for Cancer Research, Glasgow, United Kingdom.
Phone: +44-1413303655; Fax: +44-1419426521; E-mail: k.ryan@beatson.gla.ac.uk.

View the PDF of this article at:

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
8-Mar-2007


Page: 1 2 3 4 5

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents March

(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
(Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
Cached News: